Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 3/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553476 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8653785 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8654704 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8653790 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL9186701 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL30527563 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL30854410 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL15585491 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL119527 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL30792875 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002535-A1 | PEPTIDE HYDROGEL COMPRISING HYDROPHILIC AZIDE-CONTAINING AMINO ACID AND ITS USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVI | 2025-01-02 | — | — | US | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| US-12012468-B2 | Cyclic polypeptides for PCSK9 inhibition | MERCK SHARP & DOHME LLC (US) | 2024-06-18 | — | — | US | disclosed |
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230303625-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | RA PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-03-30 | — | — | US | disclosed |
| US-11530244-B2 | Cyclic polypeptides for PCSK9 inhibition | MERCK SHARP & DOHME LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210284694-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | MERCK SHARP & DOHME LLC | 2021-09-16 | — | — | US | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3810196-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | MERCK SHARP & DOHME CORP. (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2020122182-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | 中外製薬株式会社 | 2020-06-18 | — | — | WO | disclosed |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3636807-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-04-15 | — | — | EP | disclosed |
| CN-110869544-A | Cyclic peptide compound having high membrane permeability and library containing same | 中外制药株式会社 | 2020-03-06 | — | — | CN | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| EP-3507275-A1 | CXCR3 RECEPTOR AGONISTS | Celgene International II Sarl (CH) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284694-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | PCSK9, LDLR, PCSK7 | MDM4 4394/4885TP53 3599/4885CASP3 2160/4885 |
| US-20230303625-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | PCSK9, LDLR, PCSK7 | MDM4 4394/4885TP53 3599/4885CASP3 2160/4885 |
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | MDM4 4319/4885TP53 1874/4885CASP3 3601/4885 |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | VIP, SLC7A1, TRPV1 | MDM4 3636/4885TP53 1859/4885CASP3 3512/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | MDM4 4319/4885TP53 1874/4885CASP3 3601/4885 |
| US-11530244-B2 | Cyclic polypeptides for PCSK9 inhibition | PCSK9, LDLR, PCSK7 | MDM4 4394/4885TP53 3599/4885CASP3 2160/4885 |
| US-20250002535-A1 | PEPTIDE HYDROGEL COMPRISING HYDROPHILIC AZIDE-CONTAINING AMINO ACID AND ITS USE | CTH, IAPP, HTT | MDM4 1706/4885TP53 2020/4885CASP3 1656/4885 |
| US-12012468-B2 | Cyclic polypeptides for PCSK9 inhibition | PCSK9, LDLR, PCSK7 | MDM4 4394/4885TP53 3599/4885CASP3 2160/4885 |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | VIP, DNPEP, HM13 | MDM4 3098/4885TP53 3050/4885CASP3 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.